Correlation Between Antihypertensive Drugs and Survival Among Patients with Pancreatic Ductal Adenocarcinoma
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Repurposing common antihypertensive drugs shows promise for pancreatic cancer treatment. These agents may enhance chemotherapy effectiveness, offering a cost-effective strategy to improve survival in pancreatic ductal adenocarcinoma.
Area Of Science
- Oncology
- Pharmacology
- Drug Repurposing
Background
- Pancreatic cancer presents a growing prevalence with poor survival rates, necessitating novel therapeutic strategies.
- Current treatments for advanced pancreatic cancer, including chemotherapy, have limitations, especially after initial therapy.
- Drug repurposing offers a cost-effective and expedited approach to developing new anti-cancer treatments.
Purpose Of The Study
- To review preclinical and clinical evidence for using antihypertensive agents as adjunctive therapy in pancreatic cancer.
- To explore the potential of antihypertensive drugs to enhance chemotherapy efficacy and overcome treatment resistance.
- To highlight the safety profile of commonly prescribed antihypertensives in patients with comorbidities.
Main Methods
- Review of preclinical studies investigating antihypertensive agents in pancreatic cancer models.
- Analysis of clinical trial data and observational studies on antihypertensive use in pancreatic cancer patients.
- Examination of pharmacological mechanisms underlying the anti-cancer effects of antihypertensives.
Main Results
- Antihypertensive medications, including ACE inhibitors, ARBs, and CCBs, demonstrate potential anti-cancer effects.
- Evidence suggests these drugs can act as chemosensitizers, enhancing the efficacy of standard chemotherapies.
- Antihypertensives possess favorable safety profiles, suitable for patients with comorbidities common in pancreatic cancer.
Conclusions
- Antihypertensive agents represent a promising strategy for repurposing in pancreatic cancer treatment.
- Their use as adjunctive therapy could improve outcomes by targeting multiple cancer pathways and enhancing chemotherapy.
- Further clinical investigation is warranted to establish the role of antihypertensives in managing pancreatic ductal adenocarcinoma.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...